Longeveron Inc. (LGVN) company profile
Close on Nov 18, 2026Market cap $61.21MP/E –Yield –
About Longeveron
Pharmaceutical Preparations, SIC 2834
Longeveron Inc. is a clinical-stage biotechnology company that develops cellular therapies for unmet medical conditions. Its primary investigational product candidate is laromestrocel, an allogeneic cell therapy designed to promote tissue repair and reduce inflammation. The firm focuses on advancing treatments across several therapeutic indications, including hypoplastic left heart syndrome, Alzheimer’s disease, aging-related frailty, and pediatric dilated cardiomyopathy. Its customer and user base includes clinical trial participants, patients, and third-party partners seeking contract development and manufacturing services.
The company is headquartered in Miami, Florida, where it operates a manufacturing facility equipped with eight clean rooms, two research and development laboratories, and warehouse space. Its clinical operations and research activities take place in the United States, and it sponsors a patient registry program located in The Bahamas. Additionally, the organization maintains bone marrow supply agreements with multiple external partners to support product production.
Summary of the business section of Longeveron's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Longeveron Inc.
- Founded
- 2014
- Headquarters
- Miami, FL
- Address
- 1951 Nw 7th Avenue, Suite 520 33136
- Phone
- (305) 302-7158
- Website
- longeveron.com
- Employees
- 37, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Marcum LLPMarcum LLP, Hartford, CT
Stock & identifiers
- Ticker
- LGVN
- Exchange
- Nasdaq
- IPO date
- Feb 12, 2021
- Shares outstanding
- 32M, Aug 6, 2026
- Public float
- $16.49M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-10 reverse, Aug 27, 2026; 1-for-10 reverse, Mar 27, 2024
- SEC CIK
- 1721484
- CUSIP
- 54303L302
- ISIN
- US54303L3024
- FIGI
- BBG00YZ6JHT4
- Share class FIGI
- BBG00YZ6JJN6
- EIN
- 47-2174146
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Joshua Hare | Chief Scientific Officer, Director | 10,811,369 |
| Nirav S. Jhaveri | Chief Financial Officer | 29,258 |
| Paul T. Lehr | General Counsel, Secretary | 226,295 |
| Stephen H. Willard | Chief Executive Officer | 74,916 |
| Nataliya Agafonova | Chief Medical Officer | 89,564 |
| Devin Blass | CTO & SVP of CMC | 68,653 |
| Marie Washburn | Chief Financial Officer | 101,030 |
| Lisa Locklear | Chief Financial Officer | 480,005 |
| James Nathaniel Powell | Chief Executive Officer | 125,593 |
| Mohamed Wa'el Ahmed Hashad | Chief Executive Officer | 543,547 |
| Roger Joseph Hajjar | Director | 69,000 |
| Leah Rush Cann | Director | 36,000 |
| Deborah Ascheim | Director | 36,000 |
| George A. Paletta Jr. | Director | 70,000 |
| Arjun JJ Desai | Director | 36,000 |
| Ursula Ungaro | Director | 77,000 |
| Rock Soffer | Director | 964,385 |
| Khoso Baluch | Director | 67,391 |
| Richard N. Kender | Director | 33,000 |
| Neha J. Motwani | Director | 33,000 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| J. Nathaniel Powell Former Interim Chief Executive Officer | $194.39K | $112.23K | $10.63K | $135.55K | $23.03K | $475.82K | – |
| Wa’el Hashad Former Chief Executive Officer | $482.18K | $264.60K | $65.55K | – | $468.92K | $1.28M | -31% |
| Lisa A. Locklear Chief Financial Officer and Treasurer | $431.69K | $149.94K | $37.15K | $199.35K | $43.96K | $862.09K | -23% |
| Paul Lehr General Counsel and Corporate Secretary | $419.98K | $337.44K | $37.15K | $193.95K | $61.01K | $1.05M | -14% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Feb 12, 2021
- Offer price
- $10.00
- Securities offered
- 2,660,000
- Gross proceeds
- $26.60M
- Exchange
- Nasdaq
- First trading day
- Feb 12, 2021
- First-day close
- $7.41-25.9%
- Lock-up ends (est.)
- Aug 11, 2021
“The initial public offering price is $10.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 37 full-time employees plus 1 employee on leave of absence, zero part-time employees and zero full-time consultants.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 25, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Mar 9, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Sep 26, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Mar 14, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| May 10, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Mar 7, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Sep 21, 2023 | Delisting | Notice of delisting from exchange (Form 25) |
| Aug 14, 2023 | Listing | Registration of securities on an exchange (Form 8-A) |
| Mar 25, 2022 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Feb 12, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 11, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
| Feb 10, 2021 | Name change | Name changed from LONGEVERON LLC to Longeveron Inc. |
See a number that looks wrong?